跳至主要内容
临床试验/EUCTR2005-003138-16-GB
EUCTR2005-003138-16-GB进行中(未招募)1 期

A clinical observational study to assess the effectiveness of Strontium Ranelate on bone protection in osteoporotic patients pre-treated with bisphosphonates. - Strontium following bisphosphonate therapy

R+ D department, Hull and East Yorkshire NHS Hospital Trust0 个研究点目标入组 0 人开始时间: 2005年7月25日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1) - Age: 50-75
  • 2) - T score: <-2.5 at either hip or spine or a T score <2.0 and one BMD independent risk factor for fracture (previous osteoporotic fracture, maternal osteoporotic fracture, previous steroid use, BMI <19, untreated premature menopause) (typical criteria for patients considered as requiring treatment to reduced their risk of fracture).
  • 3)-Fit into group 1 or 2 below:
  • Group1: no previous bisphosphonates.
  • Group 2: > 1 year treatment with oral bisphosphonates and stopped treatment within the last 1 month due to lack of effect or side effects. Also if treated with pamidronate for > 1 year and last infusion within the last 3 month. (to allow clear distinction between the study groups)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Significant renal disease. (creatinine clearance < 30 ml/min)
  • Prior treatment with Strontium Ranelate.
  • Active malignancy
  • Osteomalacia
  • Primary hyperparathyroidism
  • Patient is unable to give informed consent

研究者

发起方
R+ D department, Hull and East Yorkshire NHS Hospital Trust

相似试验